News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Open Monoclonal Technology, Inc. Grants Unlimited Omnirat, Omnimouse And Omniflic Access To Another Global Pharmaceutical Company
January 7, 2014
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PALO ALTO, Calif.--(BUSINESS WIRE)--(OMT) today announced granting unlimited OmniRat®, OmniMouse® and OmniFlic™ access to a global leader in generics and novel pharmaceuticals.
Help employers find you! Check out all the
jobs
and
post your resume
.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Deals
Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
November 5, 2026
·
2 min read
·
Gabrielle Masson
Mergers & acquisitions
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
November 5, 2026
·
2 min read
·
Annalee Armstrong
Deals
Boehringer bets big on China, offering $7B biobucks for Sino cancer programs
November 4, 2026
·
1 min read
·
Gabrielle Masson
Deals
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
November 4, 2026
·
2 min read
·
Gabrielle Masson